The clinical significance and potential molecular mechanism of integrin subunit beta 4 in laryngeal squamous cell carcinoma
Copyright © 2019 Elsevier GmbH. All rights reserved..
The relationship between integrin beta 4 (ITGB4) expression and laryngeal squamous cell carcinoma (LSCC) remains unclarified. The object of the present study was to explore the clinical significance and potential molecular mechanism of ITGB4 in LSCC. The protein level of ITGB4 was significantly higher in 46 LSCC patients than in 26 non-LSCC tissues detected by in-house immunohistochemistry. Consistently, ITGB4 mRNA level was also greatly upregulated based on microarray and RNA-seq data (standard mean difference, SMD = 1.62, 95 % CI: 1.23-2.00). And the area under curves (AUC) of summary receiver operator characteristic (SROC) was 0.87 (95 % CI: 0.84-0.90) based on 172 cases of LSCC and 59 cases of non-cancerous controls. Ninety genes were intersected by the ITGB4 related genes and LSCC differential expressed genes (DEGs) from all available microarray and RNA-seq datasets. Based on Gene Ontology (GO) analysis, the top terms of biological process (BP), cellular component (CC) and molecular function (MF) for the 90 ITGB4 related DEGs were extracellular matrix organization, basement membrane and extracellular matrix structural constituent, respectively. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that ITGB4 related DEGs mainly participated in the pathways of ECM-receptor interaction, Focal adhesion and Small cell lung cancer. Moreover, the Protein-Protein Interaction (PPI) network indicated that ITGA3, ITGA5, ITGB4, MET, LAMA3, and COL4A1 might be the core genes of LSCC development related to ITGB4. In conclusion, high ITGB4 expression may lead to the occurrence and development of LSCC via various signaling pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:216 |
|---|---|
| Enthalten in: |
Pathology, research and practice - 216(2020), 2 vom: 15. Feb., Seite 152785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhong, Feng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ITGB4 protein, human |
|---|
| Anmerkungen: |
Date Completed 15.12.2020 Date Revised 15.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.prp.2019.152785 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304895156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304895156 | ||
| 003 | DE-627 | ||
| 005 | 20231225115953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.prp.2019.152785 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM304895156 | ||
| 035 | |a (NLM)31889588 | ||
| 035 | |a (PII)S0344-0338(19)32173-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhong, Feng |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The clinical significance and potential molecular mechanism of integrin subunit beta 4 in laryngeal squamous cell carcinoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2020 | ||
| 500 | |a Date Revised 15.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier GmbH. All rights reserved. | ||
| 520 | |a The relationship between integrin beta 4 (ITGB4) expression and laryngeal squamous cell carcinoma (LSCC) remains unclarified. The object of the present study was to explore the clinical significance and potential molecular mechanism of ITGB4 in LSCC. The protein level of ITGB4 was significantly higher in 46 LSCC patients than in 26 non-LSCC tissues detected by in-house immunohistochemistry. Consistently, ITGB4 mRNA level was also greatly upregulated based on microarray and RNA-seq data (standard mean difference, SMD = 1.62, 95 % CI: 1.23-2.00). And the area under curves (AUC) of summary receiver operator characteristic (SROC) was 0.87 (95 % CI: 0.84-0.90) based on 172 cases of LSCC and 59 cases of non-cancerous controls. Ninety genes were intersected by the ITGB4 related genes and LSCC differential expressed genes (DEGs) from all available microarray and RNA-seq datasets. Based on Gene Ontology (GO) analysis, the top terms of biological process (BP), cellular component (CC) and molecular function (MF) for the 90 ITGB4 related DEGs were extracellular matrix organization, basement membrane and extracellular matrix structural constituent, respectively. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that ITGB4 related DEGs mainly participated in the pathways of ECM-receptor interaction, Focal adhesion and Small cell lung cancer. Moreover, the Protein-Protein Interaction (PPI) network indicated that ITGA3, ITGA5, ITGB4, MET, LAMA3, and COL4A1 might be the core genes of LSCC development related to ITGB4. In conclusion, high ITGB4 expression may lead to the occurrence and development of LSCC via various signaling pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 4 | |a Integrin subunit beta 4 | |
| 650 | 4 | |a Larynx | |
| 650 | 4 | |a Microarray | |
| 650 | 4 | |a RNA-sequencing | |
| 650 | 4 | |a Squamous cell carcinoma | |
| 650 | 7 | |a ITGB4 protein, human |2 NLM | |
| 650 | 7 | |a Integrin beta4 |2 NLM | |
| 700 | 1 | |a Lu, Hui-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Yi-Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guo-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiao-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Yong-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yu-Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiao-Guohui |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ming-Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kai-Lang |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zhi-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Zhu-Xin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology, research and practice |d 1980 |g 216(2020), 2 vom: 15. Feb., Seite 152785 |w (DE-627)NLM000326879 |x 1618-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:216 |g year:2020 |g number:2 |g day:15 |g month:02 |g pages:152785 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.prp.2019.152785 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 216 |j 2020 |e 2 |b 15 |c 02 |h 152785 | ||